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BACKGROUND: Dose banding is a recently suggested dosing method that uses predefined ranges (bands) of body surface area (BSA) to
calculate each patient’s dose by using a single BSA-value per band. Thus, drugs with sufficient long-term stability can be prepared in
advance. The main advantages of dose banding are to reduce patient waiting time and improve pharmacy capacity planning; additional
benefits include reduced medication errors, reduced drug wastage, and prospective quality control. This study compares dose
banding with individual BSA dosing and fixed dose according to pharmacokinetic criteria.
METHODS: Three BSA bands were defined: BSAo1.7m2, 1.7m2pBSAo1.9m2, BSAX1.9m2 and each patient dose was calculated
based on a unique BSA-value per band (1.55, 1.80, and 2.05m2, respectively). By using individual clearance values of six drugs
(cisplatin, docetaxel, paclitaxel, doxorubicin, irinotecan, and topotecan) from 1012 adult cancer patients in total, the AUCs
corresponding to three dosing methods (BSA dosing, dose banding, and fixed dose) were compared with a target AUC for each
drug.
RESULTS: For all six drugs, the per cent variation in individual dose obtained with dose banding compared with BSA dosing ranged
between  14% and þ 22%, and distribution of AUC values was very similar with both dosing methods. In terms of reaching the
target AUC, there was no significant difference in precision between dose banding and BSA dosing, except for paclitaxel (32.0% vs
30.7%, respectively; Po0.05). However, precision was significantly better for BSA dosing compared with fixed dose for four out of six
drugs.
CONCLUSION: For the studied drugs, implementation of dose banding should be considered as it entails no significant increase in
interindividual plasma exposure.
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Drug dosing is a key issue in oncology due to the ‘dose–effect’
relationship of cytotoxics. The ideal (recommended) dose for a
specific patient is the highest dose associated with an acceptable
toxicity. This dose is known as the maximum tolerated dose
determined during the phase I trial. The current practice of using
body surface area (BSA) in dosing anticancer drugs was
implemented in clinical oncology half a century ago by Pinkel
(1958). Based on the theory that large patients have a higher
elimination capacity, it is assumed that those patients need to be
given higher doses than smaller patients to reach equal drug
concentrations. Several studies have shown that both toxicity and
efficacy of cytotoxics are related to plasma drug exposure (i.e., area
under the curve of the plasma drug concentrations vs time, AUC;
Gurney, 1996). Most of these studies and some others
(Sparreboom, 2005) have shown that the only pharmacokinetic
(PK) parameter significantly associated with individual AUC,
elimination clearance (CL), is either poorly or not correlated with
BSA for most cytotoxics (Reilly and Workman, 1993; Mathijssen
et al, 2007). As a consequence of this poor or absent correlation,
the current practice based on BSA dosing is associated with a large
interindividual variability in terms of toxicity, largely due to
heterogeneous plasma drug exposure between patients treated by
the same chemotherapy protocol. Unfortunately, for many anti-
cancer drugs currently under use, little is known concerning the
characteristics that influence clearance (and consequently are
likely to affect individual AUC), and thus no satisfactory
alternatives to BSA dosing have been suggested that could improve
the efficacy of these drugs.
Dose banding has recently been suggested to optimise
chemotherapy preparation (Plumridge and Sewell, 2001;
Pouliquen et al, 2011). Ranges (or bands) of BSA, and
corresponding mid-points of each band are predefined. The
individual dose of a particular patient is calculated according to
a single BSA-value per band, usually the mid-point of the BSA
band in which the actual BSA of the patient lies. Thanks to this
system chemotherapy provision can be rationalised and chemo-
therapies can be prepared in advance for drugs with sufficient
long-term drug stability. The main advantages of dose banding are
to reduce patient waiting time and to improve capacity planning of
the pharmacy production, but additional benefits can also be
found, such as reduced potential for medication errors, reduced
drug wastage, and prospective quality control of preparations.
While the use of dose banding is unlikely to improve efficacy, it is
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of primary importance to evaluate whether it can be shown to be
no worse than BSA dosing because of all the above-mentioned
advantages of this method.
The objective of the present analysis was to compare BSA dosing
(as the current practice), dose banding, and fixed dose according
to PK criteria. By using individual values of clearance of six drugs
(cisplatin, docetaxel, paclitaxel, doxorubicin, irinotecan, and
topotecan) from a total of 1012 adult cancer patients, the AUCs
corresponding to each of these three dosing methods were
compared with a target value of AUC for each drug.
PATIENTS AND METHODS
Data collection
The study drugs included cisplatin (n¼ 283), docetaxel (n¼ 169),
doxorubicin (n¼ 103), irinotecan (n¼ 187), paclitaxel (n¼ 80),
and topotecan (n¼ 190). These agents were considered because of
the known differences in their primary pathways of elimination.
All patients were at least 18 years old and provided written
informed consent for enrolment on studies approved by the local
review boards. Additional common eligibility criteria included: (a)
life expectancy of at least 12 weeks; (b) performance status of 0–2;
(c) no chemotherapy, hormonal therapy, or radiotherapy for at
least 4 weeks before enrolment; (d) adequate contraception and a
negative pregnancy test result for women of childbearing age; and
(e) adequate bone marrow function, renal function, and hepatic
function (i.e., patients with severe renal or hepatic impairment
were excluded). Simultaneous use of any medication, dietary
supplements, or other compounds known to inhibit, induce, or
otherwise affect the pharmacokinetics of the study drugs was not
allowed.
Sample collection and PK analysis
Preliminary PK data obtained from (subsets of) the studied patient
populations have been published previously for cisplatin (de Jongh
et al, 2001), docetaxel (Rudek et al, 2004), doxorubicin (Rudek
et al, 2004), irinotecan (de Jong et al, 2004), paclitaxel
(Henningsson et al, 2005), and topotecan (Leger et al, 2004).
Cisplatin Patients were treated with cisplatin monotherapy or
cisplatin-based combination therapy with oral etoposide, irinote-
can, oral topotecan, or docetaxel. The drug was administered as a
3-h infusion at doses ranging from 50 to 100mgm 2, with
treatment cycles repeated every week or every 3 weeks. Blood
samples were obtained immediately before infusion, at 1 and 2 h
after the start of the infusion, at the end of infusion, and at 0.5, 1, 2,
3, and 18 h after the end of infusion. Plasma concentrations of
unbound cisplatin were determined by atomic absorption spectro-
metry (de Jongh et al, 2001).
Docetaxel Patients were treated with docetaxel alone or com-
bined with capecitabine, cisplatin, doxorubicin with or without
marimastat, or methotrexate. Docetaxel was administered as a 1-h
infusion at doses ranging from 55 to 100mgm 2. Blood samples
were obtained immediately before docetaxel administration; at
30min after the start of infusion, at the end of infusion, and at 1, 3,
5, 23, and 48 h after the end of infusion. Determination of
docetaxel was performed using high-performance liquid chroma-
tography (HPLC) with UV detection (Rudek et al, 2004).
Doxorubicin Patients were treated with doxorubicin monother-
apy or with doxorubicin-based combination therapy with cyclo-
phosphamide, docetaxel, or paclitaxel. Doxorubicin was
administered as an intravenous bolus (5min), a short infusion
(15–20min), or as a 1- to 3-h infusion at doses ranging from 40 to
75mgm 2. Blood samples were taken immediately before
infusion, directly after infusion, and 30min and 1, 2, 4, 7, 12, 24,
and 48 h post infusion. Concentrations of doxorubicin in plasma
were determined by HPLC with fluorescence detection (Rudek
et al, 2004).
Irinotecan Irinotecan was administered either alone or in
combination with cisplatin as a 90-min continuous intravenous
infusion at a dose level between 175 and 350mgm 2 or at a flat
dose of 600mg. Blood samples were collected before infusion, at
0.5 and 1.5 h during infusion, and 10, 20, and 30min and 1, 2, 3,
3.5, 4, 5, 6.5, 10.5, 24, 30.5, 48, and 54.5 h after the end of infusion.
Concentrations of irinotecan and its active metabolite SN-38 were
determined by HPLC with fluorescence detection (de Jong et al,
2004).
Paclitaxel Paclitaxel was supplied as a concentrated solution in
cremophor-ethanol. The drug was administered as a single agent
or in combination with carboplatin. Paclitaxel was administered
intravenously over 1, 3, or 24 h at doses ranging from 50 to
225mgm 2. Blood samples were obtained at the following time
points: immediately before infusion, and 0.5, 1, 1.5, 2, 2.5, 3, 5, 7,
13, 25, 33, and 49 h after the start of paclitaxel infusion (1-h
schedule); 1, 2, 3, 3.08, 3.25, 3.5, 4, 4.5, 5, 7, 9, 15, 21, 27, 35, and
51 h after the start of infusion (3-h schedule); or at 1, 22, 23, 23.92,
24.08, 24.15, 25, 26, 27, 30, 36, and 45 h after the start of infusion
(24-h schedule). Determination of total paclitaxel was performed
by HPLC with UV detection (Henningsson et al, 2005).
Topotecan Topotecan was administered to patients once daily for
5 consecutive days every 3 weeks (dose, 0.2–2.4mgm 2 or a fixed
dose of 4mg), once daily for 7, 10, 13, or 21 days (dose,
0.20–1.00mgm 2), or twice daily for 5, 10, or 21 days (dose,
0.15–2.70mgm 2). The drug was administered as a single agent or
in combination with cisplatin. Sample collection was performed
before dosing, at 15min after the start of infusion, immediately
before the end of infusion, and at 15 and 30min and 1, 2, 3, 4, 6, 8,
and 10 h after the end of infusion. Determination of topotecan was
performed by HPLC with fluorescence detection (Leger et al,
2004).
Clearance, volume of distribution, and terminal half-life for each
drug were derived from individual plasma concentration-time
profiles using non-compartmental analysis with the software
package WinNonlin (Scientific Consultant, Apex, NC, USA)
Professional Version 5.0 (Pharsight Corporation, Mountain View,
CA, USA), model 202 (plasma data, constant infusion).
For each drug, the target AUC was calculated by using the mean
value of observed CL expressed in L h 1m 2, and the dose
(mgm 2) corresponding to a widely used standard protocol: target
AUC¼ standard dose (mgm 2)/mean observed CL (Lh 1m 2).
Body surface area was calculated using Dubois’ formula:
BSA (m2)¼ 0.007184 height (cm)0.725weight (kg)0.425. Three
doses were calculated for each patient: DoseBSA corresponding to
standard dose (mgm 2) multiplied by individual BSA; Dose-
FIXED corresponding to standard dose (mgm 2) multiplied by
mean BSA; DoseBAND corresponding to standard dose (mgm 2)
multiplied by relevant BSA band value: respectively 1.55, 1.80, or
2.05m2 depending on which of the following three BSA bands:
BSAo1.7m2, 1.7m2pBSAo1.9m2, or BSAX1.9m2 the BSA of the
patient belongs to. Cutoff values for the BSA bands were inspired
from a previous dose-banding methodology used by Pouliquen
et al (2011).
The relative difference between each dose calculation method
and DoseBSA was calculated in the following way: relative
difference¼ ((DoseStudiedDoseBSA)/DoseBSA) 100 (where
DoseStudied is DoseFIXED or DoseBAND). The absolute value of
relative difference¼ (|DoseStudiedDoseBSA|/DoseBSA) 100
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was also calculated. Mean and standard deviation (s.d.) for these
quantities were given as well as minimum and maximum values for
relative difference. As an indication of dose modification, the
percentage of values where absolute value of relative difference was
410% was also given.
For each patient, the AUC corresponding to each of these three
dose determination methods was calculated: Dose (mg)/actual
patient CL (L h 1) (e.g., AUCBSA¼DoseBSA/CL); the percentage
error of AUC (pi) corresponding to each dose was calculated: for
example, (AUCBSAAUCtarget) 100/AUCtarget. The absolute
value of relative difference¼ (|AUCStudiedAUCtarget|/
AUCtarget) 100 was also calculated (where AUCstudied is
AUCBSA, AUCFIXED, or AUCBAND). The precision (root mean
square error, RMSE) corresponding to each dosing method was
calculated in the following way: RMSEð % Þ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPn
i¼ 1ðpiÞ2/n
q
,
where n is the number of patients in each drug group.
The potential impact of using dose banding (DoseBAND) or
fixed dose (DoseFIXED) was evaluated in three different ways.
First, we calculated the relative difference and absolute value of the
relative difference (described above) between DoseBAND or
DoseFIXED on the one hand, and the reference DoseBSA on the
other. Second, the absolute value of the relative difference in AUCs
between DoseBAND or DoseFIXED and Dose BSA was compared
using paired Student’s t-tests. Finally, paired Student’s t-tests were
used to compare the precision (RMSE) of the AUCs obtained using
DoseBAND or DoseFIXED with the precision of the AUC obtained
with DoseBSA. For irinotecan, evaluation was performed using
both irinotecan and SN-38 AUC.
RESULTS
A total of 1012 adult cancer patients were studied. Their BSA
together with their mean PK parameters are detailed in Table 1.
For all six drugs, the per cent change in individual dose compared
with BSA dosing ranged between  14% and þ 22% for dose
banding, and  25% and þ 44% for fixed dose (Table 2). In terms
Table 1 Patient (n¼ 1012) and drug characteristics for each patient
group
Drug
Number
of
patients
BSA (m2)
Mean (s.d.)
(min–max)
Clearance
(L h1)
Mean
(CV%)
Clearance
(L h 1m 2)
Mean
(CV%)
Cisplatin 283 1.85 (0.20) (1.29–2.39) 56.2 (22.2) 30.3 (19.6)
Docetaxel 169 1.85 (0.20) (1.29–2.33) 41.7 (36.1) 22.6 (34.9)
Paclitaxel 80 1.78 (0.21) (1.32–2.38) 337.1 (26.0) 189.8 (24.0)
Doxorubicin 103 1.81 (0.21) (1.27–2.35) 63.8 (35.9) 35.4 (35.2)
Topotecan 190 1.79 (0.22) (1.36–2.39) 22.3 (29.0) 12.5 (28.0)
Irinotecan
(SN-38)
187 1.86 (0.21) (1.32–2.36) 649.5 (82.9) 347.4 (83.0)
Irinotecan
(CPT11)
187 1.86 (0.21) (1.32–2.36) 31.8 (30.6) 17.2 (31.4)
Abbreviations: BSA¼ body surface area; CV¼ coefficient of variation.
Table 2 Percentage dose variation of fixed dose method (DoseFIXED) and dose-banding method (DoseBAND) relative to dose based on individual BSA
(DoseBSA)
DoseFIXED DoseBAND
Absolute value of
relative difference Relative difference
Absolute value of
relative difference Relative difference
Usual dose per m2 (mg) Mean (s.d.) X10%a Mean (s.d.) Min Max Mean (s.d.) X10%a Mean (s.d.) Min Max
Cisplatin 80 8.9 (6.7) 37 1.2 (11.1)  23 þ 44 3.9 (2.7) 2  0.3 (4.8)  14 þ 20
Docetaxel 100 8.9 (7.0) 35 1.2 (11.3)  21 þ 43 4.1 (2.9) 3 0.01 (5.1)  12 þ 20
Paclitaxel 100 10.0 (7.6) 41 1.5 (12.5)  25 þ 35 3.9 (3.2) 4 1.4 (4.9)  14 þ 17
Doxorubicin 60 9.2 (7.3) 41 1.3 (11.7)  23 þ 42 4.1 (3.2) 4 0.003 (5.2)  13 þ 22
Topotecan 1.5 10.1 (6.8) 43 1.5 (12.2)  25 þ 31 4.4 (2.9) 4  0.4 (5.3)  14 þ 14
Irinotecan 350 9.3 (7.3) 40 1.3 (11.7)  21 þ 41 4.1 (2.9) 5  0.9 (5.0)  13 þ 17
Relative difference¼ ((DoseStudiedDoseBSA)/DoseBSA) 100 where DoseStudied is DoseFIXED or DoseBAND. Absolute value of relative difference¼ (|DoseStudied
DoseBSA|/DoseBSA) 100. aPercentage of values where absolute value of relative difference is 410%.
Table 3 Differences in plasma exposure (AUC) using each dosing method (DoseBSA, DoseFIXED and DoseBAND) compared with target AUC (usual
dose per m2/mean CL, L h 1m 2)
AUC with DoseBSA AUC with DoseBAND AUC with DoseFIXED
Absolute value
of relative difference
Absolute value of
relative difference
Absolute value of
relative difference
Drug Mean (s.d.) RMSE Mean (s.d.) RMSE Mean (s.d.) RMSE
Cisplatin 15.3 (13.7) 20.5 15.7 (13.8) 21.0 16.9* (15.8) 23.1*
Docetaxel 32.8 (32.6) 46.2 33.3 (33.1) 46.9 35.8* (36.2) 50.8*
Paclitaxel 21.8 (21.7) 30.7 23.2* (22.2) 32.0* 23.6 (25.7) 34.8*
Doxorubicin 34.6 (41.2) 53.6 34.4 (40.3) 52.9 35.7 (42.0) 55.0
Topotecan 22.3 (20.8) 30.4 23.0 (20.9) 31.1 23.8 (25.0) 34.5*
Irinotecan (SN-38) 82.0 (90.7) 122.0 81.0 (89.4) 120.5 84.7 (96.0) 127.8
Irinotecan (CPT11) 28.4 (28.9) 40.5 28.5 (27.8) 39.8 29.2 (31.0) 42.5
Abbreviations: AUC¼ area under the curve; BSA¼ body surface area; CL¼ clearance; RMSE¼ root mean square error. *Statistically significant difference (Po0.05) between
value and corresponding value with DoseBSA method.
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of capacity to attain the target AUC, precision was statistically
significantly better for BSA dosing compared with fixed dose for
four out of six drugs: cisplatin (20.5% vs 23.1%, respectively),
docetaxel (46.2% vs 50.8%), paclitaxel (30.7% vs 34.8%), and
topotecan (30.4% vs 34.5%). For the remaining two drugs, there
was no statistically significant difference in precision (doxorubi-
cin: 53.6% vs 55.0%; irinotecan (SN-38): 122.0% vs 127.8%).
However, the precision of dose banding was not significantly worse
(Po0.05) than BSA dosing, except paclitaxel (32.0% vs 30.7%,
respectively) (Table 3). The precision values were very different for
the six drugs ranging from 20% to 23% (according to dosing
method) for cisplatin to 120–128% for SN-38, the active metabolite
of irinotecan. However, for a specific drug the precision values
were very close to each other, regardless of the dosing method
used, which is a consequence of the very similar interindividual
variability in clearance expressed in L h 1m 2 compared with
values expressed in L h 1 (Table 1).
DISCUSSION
In oncology as in every area of medicine, change of practice
requires formal evaluation and validation. Current dosing practice
for cytotoxics is based on BSA since chemotherapy protocols are
evaluated according to this method during phase I to phase III
trials. Although clearance is poorly correlated with BSA (Figure 1),
this practice is partially validated by the precisions observed for
BSA dosing and fixed dose, respectively (Mathijssen et al, 2007).
Indeed, even though the precision values were very similar for BSA
dosing and dose banding, those corresponding to BSA dosing were
statistically significantly lower than those of fixed doses for
cisplatin, docetaxel, paclitaxel, and topotecan. On the contrary, for
all drugs but paclitaxel, dose banding was associated with a
precision that was not significantly worse than that of BSA dosing.
Although it was significantly different for paclitaxel, precision of
dose banding (i.e., 32.0%) was clinically similar to that of BSA
dosing (i.e., 30.7%). The distribution of the per cent error (Figures
2 and 3) confirms that dose banding is similar to BSA dosing, even
for paclitaxel.
Dose banding was first mentioned in 1996 in a brief news article
describing the system developed at the University Hospital
Birmingham National Health Science Trust. It was suggested to
rationalise chemotherapy provision. In particular, dose banding
could represent an economic interest for chemotherapy com-
pounding units. Indeed, BSA dosing implies individual prepara-
tion of doses for each patient. If chemotherapy is not administered
(mainly in case of change in dose, change in treatment, or
cancellation of treatment), then good manufacturing practices
require that unused doses be thrown away. The cost of unused
doses in case of change or cancellation of treatment could
represent about 1% of a hospital cancer drug budget (Berhoune
et al, 2011). Even if some changes in treatment could be prevented,
the cost of unused treatment due to last minute changes in dose
could not be reduced. With a dose-banding system, pharmacists
would prepare doses not for a specific patient, so in case of
cancellation of a planned dose for a patient, the prepared dose
would not be wasted but used for another patient.
In 2001, Plumridge and Sewell defined dose banding as ‘a system
whereby, through agreement between prescribers and pharmacists,
doses of intravenous cytotoxic drugs, calculated on an
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Figure 1 Relationship between body surface area (BSA) and drug clearance for all six drugs (for irinotecan, apparent clearance corresponding to SN-38
was considered). R2 values indicate the contribution of BSA to the interindividual variability in clearance.
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individualised basis, which are within defined ranges or bands, are
approximated to predetermined standard doses; the maximum
variation of the adjustment between the standard dose and the
doses constituting each band is 5% or less’ (Plumridge and Sewell,
2001). The choice we made to use only three bands covering the
total range of observed patients’ BSA (1.29–2.39m2) was associated
with a wider range of variation between the doses corresponding to
dose banding compared with those obtained using BSA dosing:
from  14% to þ 22% when considering all six drugs. The major
benefits of this strategy of limiting to three standardised doses
would be to facilitate the planning of pharmacy production, and to
reduce the number of infusion wastages (preprepared chemothera-
pies that are not used because no patient has a BSA corresponding
to that particular band). A similar analysis was performed using
five bands (rather than the three bands) with cutoff values of 1.525,
1.725, 1.875, and 2.025m2 (and corresponding values used for dose
calculation of 1.50, 1.65, 1.80, 1.95, and 2.10m2). As expected the
precision in terms of achieving target AUC was not significantly
different (data not shown). However, the benefit of this 5-band
design was to decrease the proportion of patients with dose
differing by 410% compared with individual BSA dosing (2–3%
for the 5-band method vs 2–5% for the 3-band method depending
on the drug). Hence, this 5-band system may be considered as both
more conservative and less contestable compared with the current
BSA dosing practice. However, it also limits the benefit in terms of
chemotherapy manufacturing within the hospital pharmacy
department since it exposes to more unused (wasted) chemother-
apy preparation. Another previously suggested criterion that could
be considered when fixing the standardised doses would be to have
the volumes to be taken from the commercial vials corresponding
to that of the vials of the commercial drug. If overall the precision
of dose banding is similar to that of BSA dosing, then the change in
terms of plasma AUC may be as great as the change in dose
(i.e.,  14% and þ 22% by considering our database and the
chosen dose-banding method) for a specific patient. The risk of
observing high toxicity in a patient treated using a dose 22%
higher than that which the patient would have received with BSA
dosing, may be a limiting factor for the practice of dose banding.
Indeed, one could not be certain that the 22% higher dose had no
contribution to this high toxicity. However, high toxicities of
cytotoxic treatment are observed daily due to the fact that BSA
dosing can be responsible for overexposure in patients. This begs
the question as to whether we should be more demanding for dose
banding than we are for BSA dosing. Unfortunately, toxicity and
efficacy data were not available in this study, which is why PK
variables were used as a surrogate for such clinical endpoints. We
evaluated only six cytotoxics but they present diverse PK
properties. Indeed, renal clearance represents a substantial
contribution to topotecan elimination, and cisplatin disposition
is dominated by near covalent binding of the drug to serum
proteins. The four other drugs are eliminated mainly by metabolism.
Indeed, Taxanes are metabolised by the cytochrome P450 isozymes
CYP3A4 (docetaxel) and CYP2C8 and CYP3A4 (paclitaxel), doxor-
ubicin by aldoketoreductase, and SN-38, the active metabolite of
irinotecan, by carboxylesterases and UDP glucuronosyltransferases,
including UGT1A1 (Mathijssen et al, 2001).
For SN-38, the poor precision observed whatever the method of
dose calculation used suggests that it may be relevant to explore
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Figure 2 Frequency of percentage errors between individual AUC and target AUC using BSA dosing, dose banding, or fixed dose for cisplatin, docetaxel,
and paclitaxel.
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the causes of interindividual PK variability, before administrating
irinotecan (Deeken et al, 2008). There are at least two other drugs
for which dose banding cannot be recommended from the present
work. First, 5-flurouracil pharmacokinetics is non-linear due to
saturable liver metabolism corresponding to DPD enzyme, such
that even a small change in dose could be associated with large
modifications in AUC. For example, considering a patient with
typical values of Km and Vmax (5.57mg l 1 and 51 390mgh 1,
respectively; Terret et al, 2000), an increase of 20% of 10-min IV
infusion of 500mgm 2 would be associated with a 39% increase in
AUC. The second drug is carboplatin, since for this agent, the dose is
most often calculated from GFR to target a specified AUC (Jodrell,
1999). Dose banding in this case may be based on ‘bands’ of predicted
carboplatin clearance. Additional work is needed to determine for
which other drugs the proposed strategy might have relevance.
Analytical control of chemotherapy preparation is currently in a
phase of generalisation. Some automated analytical robots are now
available. This procedure represents a step forward in terms of
increasing the safety of drug management from preparation to
administration. One of its main limits is the delay that it creates
between the physician’s prescription and the administration of the
drug to the patients. Dose banding would make it possible to
anticipate chemotherapy preparation and analytical control with-
out any delay for the patients.
In conclusion, the current evaluation of dose banding based on
PK criteria confirms the feasibility of future implementation of this
procedure in routine practice, and warrants its further evaluation
in prospective clinical trials comparing the effect of BSA-dosing
and dose-banding methods on toxicity and efficacy. In the present
study, AUC was used as it represented the best available surrogate
marker for the clinical consequences for the patient since only PK
data were available, but in the prospective study we plan to set up,
toxicity and efficacy will be assessed as well as plasma drug
exposure. Although the patient’s interest may not be evident at
first, improvement of quality control and speed of availability of
the chemotherapy on the day of the visit are two examples of
benefit to the patient which could be derived from dose banding.
Thus, in view of the important advantages of dose banding in
terms of production time gain and reduction of wastage, it is of
primary importance to evaluate whether it can be shown to be no
worse than BSA dosing. This prospective study will concern some
of the drugs evaluated and their inclusion criteria will include
morphologic patients’ characteristics corresponding to those of the
patients in the present work.
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Figure 3 Frequency of percentage errors between individual AUC and target AUC using BSA dosing, dose banding, or fixed dose for doxorubicin,
topotecan, and irinotecan (considering SN-38 concentrations).
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